WO2021091511A3 - Conjugation of protein drugs with biopolymers by an enzymatic method - Google Patents

Conjugation of protein drugs with biopolymers by an enzymatic method Download PDF

Info

Publication number
WO2021091511A3
WO2021091511A3 PCT/TR2020/051004 TR2020051004W WO2021091511A3 WO 2021091511 A3 WO2021091511 A3 WO 2021091511A3 TR 2020051004 W TR2020051004 W TR 2020051004W WO 2021091511 A3 WO2021091511 A3 WO 2021091511A3
Authority
WO
WIPO (PCT)
Prior art keywords
biopolymers
conjugation
enzymatic method
protein drugs
conjugates
Prior art date
Application number
PCT/TR2020/051004
Other languages
French (fr)
Other versions
WO2021091511A2 (en
Inventor
Ayşe Filiz ÖNER
Ayşe Göksu KAYA ÖZSAN
Original Assignee
Hacettepe Üni̇versi̇tesi̇
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hacettepe Üni̇versi̇tesi̇ filed Critical Hacettepe Üni̇versi̇tesi̇
Publication of WO2021091511A2 publication Critical patent/WO2021091511A2/en
Publication of WO2021091511A3 publication Critical patent/WO2021091511A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6955—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a plaster, a bandage, a dressing or a patch
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is related to conjugation of protein drugs with biopolymers by an enzymatic method and obtaining conjugates thereof and forming patch structures that comprises these conjugates.
PCT/TR2020/051004 2019-11-05 2020-10-27 Conjugation of protein drugs with biopolymers by an enzymatic method WO2021091511A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/17122A TR201917122A2 (en) 2019-11-05 2019-11-05 CONJUGATION OF PROTEIN DRUGS WITH BIOPOLYMERS BY ENzymatic route
TR2019/17122 2019-11-05

Publications (2)

Publication Number Publication Date
WO2021091511A2 WO2021091511A2 (en) 2021-05-14
WO2021091511A3 true WO2021091511A3 (en) 2021-06-17

Family

ID=75849027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2020/051004 WO2021091511A2 (en) 2019-11-05 2020-10-27 Conjugation of protein drugs with biopolymers by an enzymatic method

Country Status (2)

Country Link
TR (1) TR201917122A2 (en)
WO (1) WO2021091511A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029555A1 (en) * 2006-08-11 2010-02-04 Bio-Ker S.r.l G-csf site-specific mono-conjugates
US7901711B1 (en) * 2006-04-17 2011-03-08 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US20140052051A1 (en) * 2008-03-31 2014-02-20 Nitto Denko Corporation Permeant delivery system and methods for use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901711B1 (en) * 2006-04-17 2011-03-08 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US20100029555A1 (en) * 2006-08-11 2010-02-04 Bio-Ker S.r.l G-csf site-specific mono-conjugates
US20140052051A1 (en) * 2008-03-31 2014-02-20 Nitto Denko Corporation Permeant delivery system and methods for use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KAYA ÖZSAN AYŞE GÖKSU, ÖNER AYŞE FILIZ: "A new oligosaccharide-filgrastim conjugate prepared by enzymatic method: Preparation and physicochemical characterization", JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, ED. DE SANTÉ, FR, vol. 55, 1 February 2020 (2020-02-01), FR, pages 101368, XP055834713, ISSN: 1773-2247, DOI: 10.1016/j.jddst.2019.101368 *
MARINIELLO, L. ET AL.: "Transglutaminase-mediated macromolecular assembly: production of conjugates for food and pharmaceutical applications", AMINO ACIDS, vol. 46, no. 3, March 2014 (2014-03-01), pages 767 - 776, XP055834715 *
SADHASIVAM, L. ET AL.: "Transdermal patches of chitosan nanoparticles for insulin delivery", INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 7, no. 5, May 2015 (2015-05-01), pages 84 - 88, XP055834717 *
SU, F. Y. ET AL.: "Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles", BIOMATERIALS, vol. 35, no. 11, 2014, pages 3641 - 3649, XP028609482, DOI: 10.1016/j.biomaterials.2014.01.020 *

Also Published As

Publication number Publication date
WO2021091511A2 (en) 2021-05-14
TR201917122A2 (en) 2021-05-21

Similar Documents

Publication Publication Date Title
WO2018229236A3 (en) Compositions comprising bacterial strains
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
WO2016061286A3 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
BR112019008854A2 (en) peptide-containing ligands for antibody-drug conjugates
WO2011156380A3 (en) Protein-containing adhesives, and manufacture and use thereof
CA3155889A1 (en) Hydrophobic polyimide aerogels
MX2021006681A (en) Anti-claudin antibodies and uses thereof.
MX2023009205A (en) Antibody drug conjugates (adcs) having enzymatically cleavable groups.
WO2018075692A3 (en) Antibody constructs
WO2017214170A3 (en) Baff-r antibodies and uses thereof
PH12020551716A1 (en) Anti-ror antibody constructs
EP4219540A3 (en) Ctla-4 variant immunomodulatory proteins and uses thereof
WO2021021837A3 (en) Anti-pvrig antibodies formulations and uses thereof
WO2018226992A8 (en) Tau aggregation inhibitors
MX2018010491A (en) Process for the preparation of an antibody-rifamycin conjugate.
WO2020008377A3 (en) Ionic self-assembling peptides
EA201992516A1 (en) METHOD FOR PRODUCING BIFUNCTIONAL PROTEINS AND THEIR DERIVATIVES
WO2019212356A8 (en) Tetrazines for high click conjugation yield in vivo and high click release yield
WO2017079314A3 (en) Single domain antibodies directed against intracellular antigens
MX2022001719A (en) Formulations of benzazepine conjugates and uses thereof.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
WO2017015634A3 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
EP3930767A4 (en) Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20885912

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20885912

Country of ref document: EP

Kind code of ref document: A2